• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于 SARS-CoV-2 的纳米载体疫苗。

Nanocarrier vaccines for SARS-CoV-2.

机构信息

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE 68198, USA.

Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, NE 68198, USA.

出版信息

Adv Drug Deliv Rev. 2021 Apr;171:215-239. doi: 10.1016/j.addr.2021.01.002. Epub 2021 Jan 9.

DOI:10.1016/j.addr.2021.01.002
PMID:33428995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7794055/
Abstract

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

摘要

SARS-CoV-2 全球大流行迅速蔓延,与疾病发病率和死亡率相关的是重大的社会、经济和社会影响。治疗依赖于重新定位的抗病毒药物和免疫调节剂,重点是减轻急性呼吸窘迫综合征。目前还没有治愈疗法。疫苗仍然是控制疾病的最佳希望,也是全球结束大流行的主要努力。在此,我们总结了这些进展,重点介绍了纳米载体传递所发挥的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/34cc3cb4a221/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/7b6084eca2b0/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/f1092cef596f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/13eb972d4678/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/8e5951b5cd55/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/56e455eb05fc/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/34cc3cb4a221/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/7b6084eca2b0/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/f1092cef596f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/13eb972d4678/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/8e5951b5cd55/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/56e455eb05fc/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bab5/7794055/34cc3cb4a221/gr6_lrg.jpg

相似文献

1
Nanocarrier vaccines for SARS-CoV-2.用于 SARS-CoV-2 的纳米载体疫苗。
Adv Drug Deliv Rev. 2021 Apr;171:215-239. doi: 10.1016/j.addr.2021.01.002. Epub 2021 Jan 9.
2
Advances in gene-based vaccine platforms to address the COVID-19 pandemic.基于基因的疫苗平台在应对 COVID-19 大流行方面的进展。
Adv Drug Deliv Rev. 2021 Mar;170:113-141. doi: 10.1016/j.addr.2021.01.003. Epub 2021 Jan 7.
3
On the road to ending the COVID-19 pandemic: Are we there yet?走向终结新冠大流行之路:我们是否已经到达终点?
Virology. 2021 May;557:70-85. doi: 10.1016/j.virol.2021.02.003. Epub 2021 Feb 26.
4
COVID-19 vaccines: The status and perspectives in delivery points of view.COVID-19 疫苗:交付观点中的现状和展望。
Adv Drug Deliv Rev. 2021 Mar;170:1-25. doi: 10.1016/j.addr.2020.12.011. Epub 2020 Dec 24.
5
Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative.对 COVID-19 进行免疫消毒:开发辅助性 T 细胞 I 和 II 激活疫苗是当务之急。
Biomed Pharmacother. 2021 Dec;144:112282. doi: 10.1016/j.biopha.2021.112282. Epub 2021 Oct 2.
6
Intranasal COVID-19 vaccines: From bench to bed.鼻内 COVID-19 疫苗:从实验室到临床。
EBioMedicine. 2022 Feb;76:103841. doi: 10.1016/j.ebiom.2022.103841. Epub 2022 Jan 24.
7
Special focus 'SARS-CoV-2 / COVID-19: advances in developing vaccines and immunotherapeutics'.特别关注“SARS-CoV-2 / COVID-19:疫苗和免疫疗法研发进展”
Hum Vaccin Immunother. 2020 Dec 1;16(12):2888-2890. doi: 10.1080/21645515.2020.1847952.
8
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
9
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.严重急性呼吸系统综合征冠状病毒 2 刺突(S)蛋白疫苗候选物:现状与未来展望。
Rev Med Virol. 2021 May;31(3):e2183. doi: 10.1002/rmv.2183. Epub 2020 Oct 15.
10
Recombinant protein vaccines, a proven approach against coronavirus pandemics.重组蛋白疫苗,对抗冠状病毒大流行的成熟手段。
Adv Drug Deliv Rev. 2021 Mar;170:71-82. doi: 10.1016/j.addr.2021.01.001. Epub 2021 Jan 7.

引用本文的文献

1
Revolutionizing Drug Delivery: The Impact of Advanced Materials Science and Technology on Precision Medicine.变革药物递送:先进材料科学与技术对精准医学的影响。
Pharmaceutics. 2025 Mar 15;17(3):375. doi: 10.3390/pharmaceutics17030375.
2
Advances in Virus Biorecognition and Detection Techniques for the Surveillance and Prevention of Infectious Diseases.用于传染病监测与预防的病毒生物识别及检测技术进展
Biosensors (Basel). 2025 Mar 20;15(3):198. doi: 10.3390/bios15030198.
3
Revolutionizing Nanovaccines: A New Era of Immunization.

本文引用的文献

1
Adjuvants for Coronavirus Vaccines.冠状病毒疫苗佐剂。
Front Immunol. 2020 Nov 6;11:589833. doi: 10.3389/fimmu.2020.589833. eCollection 2020.
2
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中,观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性(COV002)。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
3
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
变革性纳米疫苗:免疫接种的新时代。
Vaccines (Basel). 2025 Jan 27;13(2):126. doi: 10.3390/vaccines13020126.
4
Navigating Latency-Inducing Viral Infections: Therapeutic Targeting and Nanoparticle Utilization.应对潜伏期诱导性病毒感染:治疗靶点与纳米颗粒的应用
Biomater Res. 2024 Oct 16;28:0078. doi: 10.34133/bmr.0078. eCollection 2024.
5
Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.针对 SARS-CoV-2 感染的自组装纳米颗粒疫苗的研发策略。
Front Immunol. 2024 Sep 11;15:1392898. doi: 10.3389/fimmu.2024.1392898. eCollection 2024.
6
Therapeutic and diagnostic applications of exosomes in colorectal cancer.外泌体在结直肠癌中的治疗和诊断应用。
Med Oncol. 2024 Jul 20;41(8):203. doi: 10.1007/s12032-024-02440-3.
7
Recent and advanced nano-technological strategies for COVID-19 vaccine development.用于新冠疫苗研发的最新及先进纳米技术策略
Methods Microbiol. 2022;50:151-188. doi: 10.1016/bs.mim.2022.03.001. Epub 2022 Apr 18.
8
Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System.使用疫苗不良事件报告系统分析新冠mRNA疫苗接种后的严重安全信号及预测特征
Pharmaceuticals (Basel). 2024 Mar 10;17(3):356. doi: 10.3390/ph17030356.
9
USE OF ARTIFICIAL CELLS AS DRUG CARRIERS.人工细胞作为药物载体的应用。
Mater Chem Front. 2021 Sep 21;5(18):6672-6692. doi: 10.1039/d1qm00717c. Epub 2021 Jul 16.
10
Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.鼻腔内 SARS-CoV-2 RBD 修饰纳米颗粒疫苗增强了叙利亚仓鼠模型中的病毒清除。
Microbiol Spectr. 2024 Mar 5;12(3):e0499822. doi: 10.1128/spectrum.04998-22. Epub 2024 Feb 9.
羟氯喹对 COVID-19 住院患者 14 天临床状态的影响:一项随机临床试验。
JAMA. 2020 Dec 1;324(21):2165-2176. doi: 10.1001/jama.2020.22240.
4
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.人类感染 SARS-CoV-2 后三个月内中和抗体反应的纵向观察和下降。
Nat Microbiol. 2020 Dec;5(12):1598-1607. doi: 10.1038/s41564-020-00813-8. Epub 2020 Oct 26.
5
The false promise of herd immunity for COVID-19.新冠病毒群体免疫的虚假承诺。
Nature. 2020 Nov;587(7832):26-28. doi: 10.1038/d41586-020-02948-4.
6
A promising inactivated whole-virion SARS-CoV-2 vaccine.一种有前景的灭活全病毒2019冠状病毒病疫苗。
Lancet Infect Dis. 2021 Jan;21(1):2-3. doi: 10.1016/S1473-3099(20)30832-X. Epub 2020 Oct 15.
7
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.两种基于 RNA 的新冠候选疫苗的安全性和免疫原性。
N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.
8
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.COVID-19 疫苗领跑者及其纳米技术设计。
ACS Nano. 2020 Oct 27;14(10):12522-12537. doi: 10.1021/acsnano.0c07197. Epub 2020 Oct 9.
9
Cell-Based Therapy for Severe COVID-19 Patients: Clinical Trials and Cost-Utility.基于细胞的疗法治疗重症 COVID-19 患者:临床试验和成本效益。
Stem Cell Rev Rep. 2021 Feb;17(1):56-62. doi: 10.1007/s12015-020-10046-1. Epub 2020 Oct 3.
10
A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.一名63岁有非霍奇金淋巴瘤病史且持续感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的女性,其血清学检测呈阴性,接受了恢复期血浆治疗。
Am J Case Rep. 2020 Oct 3;21:e927812. doi: 10.12659/AJCR.927812.